| Literature DB >> 33655951 |
Sihan Li1,2, Jiajie Peng3, Ruoying Xu2, Rong Zheng2, Minghan Huang2, Yongzhen Xu4, Youcheng He2, Yujuan Chai5, Hongmei Song2, Tetsuya Asakawa6,7.
Abstract
OBJECTIVE: We designed and performed a network meta-analysis to compare the clinical outcomes among the 5 surgeries-anterior cervical corpectomy and fusion (ACCF), anterior controllable antedisplacement fusion (ACAF), laminoplasty (LP), laminectomy (LC), and posterior decompression with instrumented fusion (PDF)-for patients with cervical spondylosis related to the ossification of the posterior longitudinal ligament (OPLL).Entities:
Mesh:
Year: 2021 PMID: 33655951 PMCID: PMC7939206 DOI: 10.1097/MD.0000000000024900
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Figure 1Flow chart of the strategy used for identifying and selecting suitable literature reports.
Characteristics of the included studies.
| Authors | Design | Interventions | Sample size | Average age (MD, SD) | Sex (M/F) | Follow-up, mo |
| Chen et al, 2011[ | R | 1 vs 2 vs 2 | 22 vs 25 vs 28 | 57.2 vs 54.2 vs 55.3 | 14/8 vs 16/9 vs 19/9 | >48 |
| Chen et al 2012[ | R | 1 vs 2 vs 2 | 91 vs 41 vs 32 | 48.7 vs 46.3 vs 52.6 | 63/28 vs 33/8 vs 19/13 | >48 |
| Fujimori et al, 2014[ | R | 1 vs 2 | 12 vs 15 | 55.6 vs 58.7 | 7/5 vs 12/3 | >24 |
| Hou et al, 2018[ | R | 2 vs 5 | 22 vs 17 | 46.1 vs 44.5 | 14/8 vs 11/6 | 15.27 vs 16.01 |
| Iwasaki et al, 2007[ | R | 1 vs 2 | 27 vs 66 | 58 vs 57 | 15/12 vs 51/15 | 72 vs 122.4 |
| Katsumi et al 2016[ | R | 2 vs 2 | 22 vs 19 | 59 vs 61 | 14/8 vs 14/5 | 52 ± 19 vs 51 ± 21 |
| Kim et al, 2015[ | R | 1 vs 2 | 71 vs 64 | 57.3 vs 56.4 | 51/20 vs 49/15 | 48 vs 41 |
| Koda et al, 2016[ | R | 1 vs 2 vs 2 | 15 vs 16 vs 17 | 57.7 vs 60.3 vs 65.0 | 10/5 vs 12/4 vs 14/3 | 58.6 vs 46.0 vs 42.0 |
| Lee et al, 2008[ | R | 1 vs 2 | 20 vs 27 | 56.8 vs 54.7 | 15/5 vs 26/1 | 21.8 vs 29.1 |
| Lee et al, 2016[ | R | 2 vs 2 vs 4 | 21 vs 21 vs 15 | 54.2 vs 63.7 vs 61.3 | 15/6 vs 19/2 vs 13/2 | >24 |
| Lin et al, 2012[ | R | 1 vs 2 | 26 vs 30 | 54.7 vs 56.2 | 15/11 vs 17/13 | 36.3 ± 6.4 vs 37.6 ± 6.7 |
| Liu et al, 2013[ | R | 1 vs 2 | 68 vs 59 | 54.4 vs 57.9 | 36/32 vs 25/34 | 81.6 |
| Liu et al, 2017[ | R | 2 vs 2 | 32 vs 35 | 59 vs 60 | 26/6 vs 25/10 | 38 ± 13 vs 42 ± 9 |
| Masaki et al, 2007[ | R | 1 vs 2 | 19 vs 40 | 51.8 vs 62.6 | 14/5 vs 30/10 | ≥ 12 |
| Mizuno and Nakagawa, 2006[ | R | 1 vs 2 | 111 vs 10 | N/A | N/A | ≥ 24 |
| Ota et al, 2016[ | R | 2 vs 2 | 23 vs 27 | 59.8 vs 63.7 | 20/3 vs 23/4 | 47.2 ± 29.3 vs 45.4 ± 32.6 |
| Sakai et al, 2012[ | P | 1 vs 2 | 20 vs 22 | 59.5 vs 58.4 | 3.67 | 50 |
| Tani et al, 2002[ | R | 1 vs 2 | 14 vs 12 | 62 vs 66 | 11/3 vs 9/3 | 49 ± 34 vs 50 ± 43 |
| Yang et al, 2018[ | R | 1 vs 5 | 36 vs 34 | 58.4 vs 58.6 | 19/17 vs 21/13 | 12.4 ± 4.7 vs 10.1 ± 2.8 |
| Yoo et al, 2017[ | R | 2 vs 4 | 38 vs 35 | 60.93 vs 64.57 | 30/8 vs 25/10 | 35.17 ± 15.91 vs 40.93 ± 22.94 |
| Yoshii et al, 2016[ | R | 1 vs 2 | 39 vs 22 | 61.1 vs 60.6 | 31/8 vs 18/4 | 44.5 ± 18.8 vs 37.2 ± 16.3 |
| Yuan et al, 2015[ | P | 2 vs 2 | 20 vs 18 | 59 vs 62 | 14/6 vs 11/7 | 12 |
Assessment of the study quality.
| Authors | Selection | Comparability | Outcome | Total |
| Chen et al, 2011[ | 3 | 1 | 2 | 6 |
| Chen et al, 2012[ | 3 | 2 | 2 | 7 |
| Fujimori et al 2014[ | 2 | 1 | 3 | 6 |
| Hou et al, 2018[ | 3 | 1 | 3 | 7 |
| Iwasaki et al, 2007[ | 3 | 1 | 2 | 6 |
| Katsumi et al, 2016[ | 2 | 1 | 3 | 6 |
| Kim et al, 2015[ | 3 | 2 | 3 | 8 |
| Koda et al, 2016[ | 3 | 1 | 3 | 7 |
| Lee et al, 2008[ | 3 | 1 | 3 | 7 |
| Lee et al, 2016[ | 3 | 1 | 2 | 6 |
| Lin et al, 2012[ | 3 | 2 | 3 | 8 |
| Liu et al, 2013[ | 3 | 2 | 3 | 8 |
| Liu et al, 2017[ | 3 | 2 | 2 | 8 |
| Masaki et al, 2007[ | 3 | 2 | 3 | 8 |
| Mizuno and Nakagawa, 2006[ | 4 | 1 | 3 | 8 |
| Ota et al, 2016[ | 3 | 1 | 3 | 7 |
| Sakai et al, 2012[ | 4 | 2 | 3 | 9 |
| Tani et al, 2002[ | 3 | 1 | 2 | 7 |
| Yang et al, 2018[ | 3 | 1 | 3 | 7 |
| Yoo et al, 2017[ | 3 | 1 | 3 | 7 |
| Yoshii et al, 2016[ | 3 | 1 | 2 | 6 |
| Yuan et al, 2015[ | 3 | 1 | 3 | 7 |
Results of the node-splitting analysis.
| Endpoints | Comparison | Direct effect | Indirect effect | Overall | |
| JOA | 1 vs 2 | −1.55 (−2.77 to −0.42) | −1.05 (−4.00 to 1.95) | −1.40 (−2.49 to −0.37) | .74 |
| 1 vs 3 | −1.62 (−3.37 to −0.03) | −0.68 (−4.24 to 2.81) | −1.31 (−2.78 to 0.09) | .59 | |
| 1 vs 5 | 0.88 (−2.32 to 4.12) | −1.90 (−5.41 to 1.62) | −0.32 (−2.73 to 2.11) | .23 | |
| 2 vs 3 | 0.27 (−1.52 to 2.09) | 0.94 (−2.79 to 4.74) | 0.09 (−1.34 to 1.53) | .72 | |
| 2 vs 5 | −0.36 (−3.76 to 3.05) | 2.45 (−0.91 to 5.92) | 1.09 (−1.31 to 3.48) | .22 | |
| IR | 1 vs 2 | −23.38 (−39.63 to −7.81) | −22.20 (−70.20 to 25.76) | N/A | .96 |
| 1 vs 3 | −16.05 (−37.63 to 5.26) | −17.29 (−63.91 to 27.72) | N/A | .96 | |
| 2 vs 3 | 9.39 (−14.14 to 33.88) | 19.88 (−30.56 to 70.07) | N/A | .69 | |
| Excellent and good recovery rate | 2 vs 3 | 1.03 (−1.78 to 4.16) | 0.92 (−2.25 to 4.19) | 0.65 (−1.25 to 2.59) | .94 |
| Lordosis | 1 vs 2 | −3.26 (−8.69 to 2.27) | −2.13 (−11.16 to 7.47) | −2.99 (−7.61 to 2.00) | .82 |
| 1 vs 3 | −1.00 (−7.69 to 5.61) | −2.08 (−10.92 to 6.51) | −0.99 (−6.31 to 4.09) | .83 | |
| 2 vs 3 | 1.87 (−4.01 to 7.07) | 4.05 (−9.54 to 16.97) | 2.02 (−2.96 to 6.39) | .74 | |
| 3 vs | −3.38 (−16.73 to 9.84) | −0.27 (−13.08 to 13.17) | −1.72 (−10.31 to 7.12) | .71 | |
| Time | 1 vs 2 | −119.46 (−199.03 to −42.34) | −77.78 (−198.92 to 45.53) | −111.01 (−177.65 to −43.66) | .52 |
| 1 vs 3 | −16.38 (−121.76 to 88.16) | −5.31 (−134.00 to 122.00) | −7.71 (−88.76 to 71.94) | .88 | |
| 1 vs 5 | 39.42 (−121.90 to 196.45) | −118.99 (−288.39 to 52.12) | −33.38 (−158.24 to 93.49) | .16 | |
| 2 vs 3 | 122.78 (33.34 to 211.37) | 55.04 (−92.42 to 201.66) | 103.32 (27.93 to 177.74) | .39 | |
| 2 vs 5 | 4.72 (−156.52 to 163.71) | 163.12 (−11.54 to 336.09) | 77.44 (−46.71 to 204.01) | .15 | |
| Blood loss | 1 vs 2 | −96.93 (−352.38 to 163.71) | −168.38 (−570.55 to 245.19) | 137.69 (−343.15 to 70.77) | .74 |
| 1 vs 3 | 57.94 (−250.14 to 421.04) | 233.49 (−164.35 to 623.77) | 121.41 (−120.49 to 386.13) | .47 | |
| 1 vs 5 | 12.59 (−520.19 to 558.80) | −188.00 (−773.52 to 399.13) | −81.14 (−455.44 to 294.47) | .56 | |
| 2 vs 3 | 351.28 (132.52 to 580.72) | −58.64 (−400.83 to 322.89) | 259.15 (33.66 to 510.13) | .06 | |
| 2 vs 5 | −33.76 (−584.86 to 523.64) | 165.01 (−425.09 to 762.74) | 55.03 (−316.25 to 431.70) | .58 | |
| Complication | 1 vs 2 | −0.80 (−1.90 to 0.21) | −0.83 (−2.52 to 0.84) | −0.79 (−1.68 to 0.05) | .98 |
| 1 vs 3 | −0.78 (−2.19 to 0.48) | 0.21 (−1.51 to 1.89) | −0.39 (−1.44 to 0.60) | .33 | |
| 1 vs 4 | 2.68 (−0.07 to 5.49) | −0.89 (−3.09 to 1.18) | 0.42 (−1.45 to 2.21) | ||
| 1 vs 5 | −1.70 (−4.96 to 1.38) | −1.33 (−4.43 to 1.70) | −1.51 (−3.69 to 0.54) | .87 | |
| 2 vs 3 | 0.53 (−0.46 to 1.50) | −0.39 (−2.44 to 1.76) | 0.39 (−0.58 to 1.35) | .42 | |
| 2 vs 4 | 0.04 (−2.12 to 2.06) | 3.62 (0.76 to 6.60) | 1.20 (−0.56 to 2.96) | .05 | |
| 2 vs 5 | −0.52 (−3.48 to 2.46) | −0.91 (−4.30 to 2.35) | −0.72 (−2.88 to 1.35) | .86 | |
| 3 vs 4 | −0.76 (−4.91 to 2.75) | 1.55 (−0.68 to 3.86) | 0.81 (−1.06 to 2.72) | .26 |
Figure 2Network plots of comparative interventions. The width of the black line presents the number of trials compared in each treatment pair. The size of the blue circle represents the sample size of the corresponding intervention.
Estimated effects of the network meta-analysis.
| Items | ACCF | LP | LC | ACAF | |
| JOA | |||||
| ACCF | 1 | ||||
| LP | 1.42 (0.38 to 2.53) | 1 | |||
| 1.31 (−0.09 to 2.76) | −0.10 (−1.56 to 1.33) | 1 | |||
| LC | 1.95 (−1.39 to 5.37) | 0.54 (−2.66 to 3.72) | 0.65 (−2.82 to 4.18) | 1 | |
| ACAF | 0.31 (−2.05 to 2.80) | −1.10 (−3.53 to 1.37) | −0.99 (−3.66 to 1.77) | −1.65 (−5.66 to 2.46) | 1 |
| IR | |||||
| ACCF | 1 | ||||
| LP | 22.64 (8.24 to 37.22) | 1 | |||
| 14.27 (−3.67 to 32.86) | −8.28 (−26.48 to 10.04) | 1 | |||
| LC | 30.09 (−13.30 to 74.17) | 7.62 (−33.71 to 49.06) | 16.13 (−29.26 to 60.79) | 1 | |
| ACAF | −10.78 (−52.16 to 30.07) | −33.37 (−77.22 to 10.34) | −25.05 (−70.73 to 19.85) | −40.94 (−102.27 to 18.53) | 1 |
| Excellent and good recovery rate | |||||
| ACCF | 1 | ||||
| LP | 3.11 (1.14 to 9.89) | 1 | |||
| 1.65 (0.29 to 10.52) | 0.53 (0.07 to 3.54) | 1 | |||
| Lordosis | |||||
| ACCF | 1 | ||||
| LP | 2.92 (−2.02 to 7.54) | 1 | |||
| 0.97 (−4.15 to 6.35) | −1.95 (−6.34 to 3.03) | 1 | |||
| LC | 2.62 (−6.65 to 11.91) | −0.30 (−8.30 to 7.90) | 1.64 (−7.28 to 10.36) | 1 | |
| ACAF | −6.75 (−19.86 to 6.46) | −9.63 (−21.81 to 2.75) | −7.70 (−21.03 to 5.33) | −9.42 (−24.32 to 5.23) | 1 |
| Operative time | |||||
| ACCF | 1 | ||||
| LP | 110.20 (44.30 to 178.15) | 1 | |||
| 6.90 (−73.05 to 86.98) | −103.31 (−178.56 to −29.73) | 1 | |||
| ACAF | 32.88 (−92.28 to 158.43) | −77.20 (−202.23 to 46.35) | 25.74 (−113.63 to 165.50) | NA | 1 |
| Blood loss | |||||
| ACCF | 1 | ||||
| LP | 135.57 (−67.34 to 344.65) | 1 | |||
| −125.44 (−389.19 to 121.68) | −260.82 (−509.87 to −36.80) | 1 | |||
| ACAF | 80.42 (−293.97 to 463.60) | −55.58 (−433.69 to 312.13) | 204.46 (−208.80 to 646.39) | NA | 1 |
| Complications | |||||
| ACCF | 1 | ||||
| LP | 2.37 (0.92 to 6.46) | 1 | |||
| 1.54 (0.50 to 4.89) | 0.65 (0.22 to 1.80) | 1 | |||
| LC | 0.96 (0.14 to 8.53) | 0.41 (0.06 to 3.34) | 0.62 (0.08 to 5.84) | 1 | |
| ACAF | 4.67 (0.46 to 49.92) | 1.98 (0.18 to 20.22) | 3.01 (0.26 to 36.58) | 4.85 (0.22 to 88.51) | 1 |
Figure 3Rank probability of the interventions.